It’s the latest in a series of new drugs for a devastating, lifelong disease.
It’s also the first of its kind in Europe.
It was developed by a team from the University of Pittsburgh.
It has the potential to save lives and change lives in hospitals and other settings around the world.
A study of about 2,500 people who had been taking the drug showed that nearly half of them had reduced their risk of dying from cancer, according to Dr. Mina Marchetti, lead researcher of the trial.
It also significantly reduced the rate of pneumonia and heart attacks, the researchers reported in Nature Medicine.
“It’s a really important discovery,” Marcheti said.
The first-of-its-kind drug is being tested in the United States at a medical center in Atlanta, Ga., and a Phase 2 clinical trial is underway in the UK. “
There are many other therapies in use that we don’t know how to get around COPD, but this is the first time we’ve been able to get a drug that does not have any side effects.”
The first-of-its-kind drug is being tested in the United States at a medical center in Atlanta, Ga., and a Phase 2 clinical trial is underway in the UK.
This is a new type of drug that has never been tested in human trials before.
The research is supported by the National Institutes of Health, National Cancer Institute and the German Research Foundation.
“We know that it is a very important tool in COPD control,” Marcetti said.
One of the drugs is called Zirconia, which has been used for more than 20 years to reduce COPD symptoms and prevent lung cancer.
The drug was approved by the U.S. Food and Drug Administration in 2009, and the U